{
    "root": "c11ff279-c752-44b6-bf85-a7c86670fd4c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Mirtazapine",
    "value": "20240716",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "MIRTAZAPINE",
            "code": "A051Q2099Q"
        }
    ],
    "indications": "Mirtazapine tablets are indicated for the treatment of major depressive disorder (MDD) in adults \n                        [see Clinical Studies (14)].",
    "contraindications": "• Starting dose: 15-mg once daily; may increase up to maximum recommended dose of 45 mg once daily. (2.1) • Administer orally once daily, preferably in the evening prior to sleep. (2.1) • Reduce dose gradually when discontinuing mirtazapine tablets. ( 2.6 , 5.14 )",
    "warningsAndPrecautions": "Mirtazapine tablets, USP are supplied as:\n                  30 mg - Reddish-brown, oval, biconvex tablet - film coated tablets with “500” debossed on one side and scored on the other side.\n                  NDC 72162-1640-02 Bottle of 45 tablets\n                  NDC 72162-1640-03 Bottle of 30 tablets\n                  NDC 72162-1640-05 Bottle of 500 tablets \n                  NDC 72162-1640-00 Bottle of 1000 tablets\n                  \n                     \n                        Storage\n                     \n                  \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted 15° to 30°C (59° to 86°F). [see USP Controlled Room Temperature]. Protect from light and moisture.\n                  Repackaged/Relabeled by:\n                  Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions": "Mirtazapine tablets are contraindicated in patients: \n                  \n                     \n                        •Taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome \n                           [see Warnings and Precautions (5.3), Drug Interactions (7)].\n                        \n                     \n                     \n                        •With a known hypersensitivity to mirtazapine or to any of the excipients in mirtazapine tablets. Severe skin reactions, including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome, bullous dermatitis, erythema multiforme and toxic epidermal necrolysis have been reported following the use of mirtazapine tablets \n                           [see Warnings and Precautions (5.6), Adverse Reactions (6.2)]."
}